Digital Asset DirectBack to School Ready 2024
News Media Group, Inc.
Contact Details News Media Group, Inc. Karl Wayne +1 334-440-6397 karl@newsmg.com Company Website https://newsmg.com/
August 08, 2024 01:33 PM Eastern Daylight Time
Video
Digital Asset Direct
News ReleaseTHE WORLD’S FIRST IMMERSIVE GAMING EXPERIENCE TO LAUNCH SECOND HOUSTON LOCATION THIS AUGUST
Activate
Activate, the pioneering live-action gaming venue and viral sensation on TikTok, is thrilled to announce the grand opening of its second location in Houston on August 16, 2024, after a successful opening in Katy. This unique and dynamic venue offers guests the chance to immerse themselves in the nationwide gaming phenomenon. Activate The Woodlands is located at 536 Sawdust Rd, Suite C, Spring, TX 77380. Activate is revolutionizing the gaming landscape, extending its reach across the United States with 40 successful locations worldwide and an unstoppable momentum. Boasting a global player base of over 2.5 million, this exciting experience combines cutting-edge technology with thrilling challenges, providing an electrifying social adventure. "Activate is excited to expand its footprint by opening a second location in Houston to meet the growing demand for immersive, interactive experiences among residents and visitors,” says Will Gray, Director of Marketing at Activate. "This new venue will allow a broader audience to experience the unique mix of physical activity and digital gaming that Activate is known for. We're excited to bring this thrill to a new market and engage more adventurers.” From August 23 to 25, Activate is hosting its Grand Opening Weekend with special surprises, the likes of which they have never done before. The new venue will offer a broader audience the opportunity to enjoy the unique blend of physical activity and digital gaming that Activate is renowned for. Activate The Woodland's cutting-edge gaming facility invites players of all ages and skill levels to explore and create their own unique gaming experiences. Here’s what to expect: Guests can sign up in groups of two to five players Through progress tracking via Activate’s high-tech electronic RFID wristbands, players can rack up points, leveling up and earning prizes along the way. Top gaming rooms include the TikTok viral sensation Mega Grid with 500+ multi-activated rainbow-coloured tiles, blasting the beaming bullseye in a game called Strike, and feel like a modern day spy in the Laser room. Try Level 1 easy or take it to Level 10 extreme. Play as a team in cooperative mode, or challenge your friends in competitive mode games. Additional Activate locations are set to open in 2024 across the U.S. in markets such as Columbus, Detroit, St. Louis, a third location in the Dallas Fort Worth Metroplex, Cleveland, and New York City, along with internationally in the UK and UAE. Today, Activate operates over 40 locations across Canada and the U.S. PLAN YOUR VISIT Wear activewear and flat, closed-toe shoes. Where: 536 Sawdust Rd., Suite C, Spring, TX 77380. When: Monday through Thursday, 10 a.m. to 10 p.m. | Friday, 10 a.m to 11 p.m | Saturday, 9 a.m. to 11 p.m. | Sunday, 9 a.m. to 10 p.m. Cost: Starting at 19.99 per player Mon-Thurs and 24.99 per player Fri-Sun (And Holidays) For a sneak peek into Activate’s action-packed gaming experience, click here. Click here for high-res assets ### Activate is the world's first active gaming experience where players #EnterTheGame. Activate offers a unique blend of physical activity and gaming that promotes a healthy lifestyle. Each Activate location provides fun and interactive rooms for players to compete, earn stars and track achievements. With the global headquarters located in Winnipeg, Canada, Activate has grown to 40 locations across Canada, and the U.S. To join the active gaming movement, visit Activate and follow on social media: Facebook: Activate Instagram: @activategames TikTok: @activategames Contact Details Jive PR + Digital Jalila Singerff +1 613-614-6777 jalila@jiveprdigital.com Company Website https://playactivate.com
August 08, 2024 09:00 AM Eastern Daylight Time
News ReleaseAlzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease
MarketJar
Mental health issues are on the rise, affecting almost 60 million US adults and more than 970 million people worldwide. 1 Rising cases has led to an uptick in new treatments moving through the clinical stages, including Alzamend Neuro, Inc. (NASDAQ:ALZN), which is focused on developing next-generation treatments for Alzheimer’s disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). Among its promising pipeline, AL001 stands out as a potential game-changer for bipolar disorder treatment. Alzamend Neuro 's AL001, a patented ionic cocrystal technology, aims to deliver lithium in a way that reduces toxicity while maintaining therapeutic efficacy by combining lithium, salicylate, and L-proline. Alzamend Neuro is rapidly advancing treatments for mental health disorders, potentially accelerating clinical phase progress due to the successes of AL001 in a Phase I and Phase IIA clinical trials for the treatment of Alzheimer’s. In 2023, the company filed IND applications for Phase IIA Clinical Trials of AL001 for Bipolar Disorder, MDD and PTSD. By the end of 2023, the FDA granted approval for these studies via “Study may proceed” letters. Alzamend Neuro Partners with MGH for Phase II Trial of Next-Generation Lithium Therapeutic Drug Candidate for Bipolar Disorder On August 6th, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced a partnership with Massachusetts General Hospital (MGH) to conduct a Phase II clinical trial of AL001 for treatment of patients with bipolar disorder. MGH, the primary clinical education and research facility of Harvard Medical School, is the world's largest hospital-based research program. Dr. Ovidiu Andronesi MD, PhD, Associate Professor of Radiology at Harvard University and Director of Multinuclear Metabolic Imaging at the Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, will lead the study as the Principal Investigator. The trial will compare AL001 to a marketed lithium carbonate product, focusing on bioavailability and brain distribution of lithium, with the goal of establishing AL001's safe, effective, and tolerable dosing requirements. AL001 is designed to offer the therapeutic benefits of traditional lithium salts while minimizing their toxic side effects. This head-to-head study will measure lithium levels in the brain and structures of bipolar disorder patients, building on mouse studies that suggest AL001 can achieve therapeutic benefits at lower doses. The study will also leverage brain imaging to predict the efficacy and safety of AL001 compared to existing lithium treatments. Alzamend Neuro 's previous Phase IIA studies of AL001 in Alzheimer's patients and healthy subjects have demonstrated a benign safety profile, identifying a candidate dose unlikely to require therapeutic drug monitoring (TDM). This is a significant advancement, as current lithium treatments require rigorous monitoring due to their narrow therapeutic window and potential toxicity. “We are elated to partner with Massachusetts General Hospital and Dr. Andronesi in this pivotal study for our lead therapeutic candidate AL001,” said Alzamend Neuro, Inc. (NASDAQ:ALZN) CEO Stephan Jackman, “If we can develop a next-generation lithium product (AL001) with an improved safety profile and enhanced biodistribution in the brain that would not routinely require therapeutic drug monitoring (TDM), it would constitute a major improvement over current lithium-based treatments and positively impact the 7+ million Americans afflicted with bipolar disorder. We look forward to providing more details regarding study timelines and market opportunity in the near future.” This innovation has the potential to positively impact the over 7 million Americans living with bipolar disorder. Further details about the study timelines and market potential will be shared soon. Alzamend Neuro to Conduct a Phase II Clinical Trial of AL001, involving Patients with Alzheimer’s Disease Alzamend Neuro, Inc. (NASDAQ:ALZN) also just announced a collaboration with Massachusetts General Hospital (MGH) to conduct A Phase II clinical trial for AL001, for the potential treatment of Alzheimer's disease. This trial will involve both Alzheimer’s patients and healthy subjects to compare the bioavailability and brain distribution of AL001 versus a marketed lithium carbonate product. The trial, which will also be led by Dr. Ovidiu Andronesi of Harvard University, aim to establish AL001's safe, effective, and tolerable dosing requirements. The potential to avoid the need for therapeutic drug monitoring (TDM) is also significant, as it could simplify treatment regimens and improve patient compliance. By potentially offering a safer and more effective alternative to traditional lithium treatments, AL001 could revolutionize how Alzheimer's disease is managed. The ability to measure lithium levels directly in the brain and brain structures using advanced imaging techniques will provide invaluable insights into the drug’s efficacy and safety. This approach not only enhances our understanding of how AL001 works but also supports its potential approval through a Section 505(b)(2) pathway with the FDA. If successful, the trial could pave the way for a new era in Alzheimer's treatment, providing hope for millions of patients and their families. Financial Support for Clinical Trial In addition to this groundbreaking partnership, Alzamend Neuro, Inc. (NASDAQ:ALZN) recently secured the first two tranches of a $25 million Series A purchasing agreement. This investment supports the advancement of Alzamend 's clinical trial and the development of next-generation treatments for Alzheimer’s, bipolar disorder, MDD, and PTSD. CEO Stephan Jackman emphasized the company's dedication to advancing clinical milestones and revolutionizing lithium-based therapies for millions affected by these conditions. Click here for more information about Alzamend Neuro, Inc. (NASDAQ:ALZN). [1] https://www.who.int/health-topics/mental-health#tab=tab_2 Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Alzamend Neuro, Inc. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-alzn. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Alzamend Neuro, Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Alzamend Neuro, Inc.’s industry; (b) market opportunity; (c) Alzamend Neuro, Inc.’s business plans and strategies; (d) services that Alzamend Neuro, Inc. intends to offer; (e) Alzamend Neuro, Inc.’s milestone projections and targets; (f) Alzamend Neuro, Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Alzamend Neuro, Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Alzamend Neuro, Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Alzamend Neuro, Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Alzamend Neuro, Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Alzamend Neuro, Inc.’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Alzamend Neuro, Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Alzamend Neuro, Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Alzamend Neuro, Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Alzamend Neuro, Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Alzamend Neuro, Inc.’s business operations (e) Alzamend Neuro, Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Alzamend Neuro, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Alzamend Neuro, Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Alzamend Neuro, Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Alzamend Neuro, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Alzamend Neuro, Inc. or such entities and are not necessarily indicative of future performance of Alzamend Neuro, Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on pressreach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com
August 06, 2024 11:45 AM Eastern Daylight Time
Image
News ReleaseHeadline
MarketJar
Mental health issues are on the rise, affecting almost 60 million US adults and more than 970 million people worldwide. 1 Rising cases has led to an uptick in new treatments moving through the clinical stages, including Alzamend Neuro, Inc. (NASDAQ:ALZN), which is focused on developing next-generation treatments for Alzheimer’s disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). Among its promising pipeline, AL001 stands out as a potential game-changer for bipolar disorder treatment. Alzamend Neuro 's AL001, a patented ionic cocrystal technology, aims to deliver lithium in a way that reduces toxicity while maintaining therapeutic efficacy by combining lithium, salicylate, and L-proline. Alzamend Neuro is rapidly advancing treatments for mental health disorders, potentially accelerating clinical phase progress due to the successes of AL001 in a Phase I and Phase IIA clinical trials for the treatment of Alzheimer’s. In 2023, the company filed IND applications for Phase IIA Clinical Trials of AL001 for Bipolar Disorder, MDD and PTSD. By the end of 2023, the FDA granted approval for these studies via “Study may proceed” letters. Alzamend Neuro Partners with MGH for Phase II Trial of Next-Generation Lithium Therapeutic Drug Candidate for Bipolar Disorder On August 6th, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced a partnership with Massachusetts General Hospital (MGH) to conduct a Phase II clinical trial of AL001 for treatment of patients with bipolar disorder. MGH, the primary clinical education and research facility of Harvard Medical School, is the world's largest hospital-based research program. Dr. Ovidiu Andronesi MD, PhD, Associate Professor of Radiology at Harvard University and Director of Multinuclear Metabolic Imaging at the Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, will lead the study as the Principal Investigator. The trial will compare AL001 to a marketed lithium carbonate product, focusing on bioavailability and brain distribution of lithium, with the goal of establishing AL001's safe, effective, and tolerable dosing requirements. AL001 is designed to offer the therapeutic benefits of traditional lithium salts while minimizing their toxic side effects. This head-to-head study will measure lithium levels in the brain and structures of bipolar disorder patients, building on mouse studies that suggest AL001 can achieve therapeutic benefits at lower doses. The study will also leverage brain imaging to predict the efficacy and safety of AL001 compared to existing lithium treatments. Alzamend Neuro 's previous Phase IIA studies of AL001 in Alzheimer's patients and healthy subjects have demonstrated a benign safety profile, identifying a candidate dose unlikely to require therapeutic drug monitoring (TDM). This is a significant advancement, as current lithium treatments require rigorous monitoring due to their narrow therapeutic window and potential toxicity. “We are elated to partner with Massachusetts General Hospital and Dr. Andronesi in this pivotal study for our lead therapeutic candidate AL001,” said Alzamend Neuro, Inc. (NASDAQ:ALZN) CEO Stephan Jackman, “If we can develop a next-generation lithium product (AL001) with an improved safety profile and enhanced biodistribution in the brain that would not routinely require therapeutic drug monitoring (TDM), it would constitute a major improvement over current lithium-based treatments and positively impact the 7+ million Americans afflicted with bipolar disorder. We look forward to providing more details regarding study timelines and market opportunity in the near future.” This innovation has the potential to positively impact the over 7 million Americans living with bipolar disorder. Further details about the study timelines and market potential will be shared soon. Alzamend Neuro to Conduct a Phase II Clinical Trial of AL001, involving Patients with Alzheimer’s Disease Alzamend Neuro, Inc. (NASDAQ:ALZN) also just announced a collaboration with Massachusetts General Hospital (MGH) to conduct A Phase II clinical trial for AL001, for the potential treatment of Alzheimer's disease. This trial will involve both Alzheimer’s patients and healthy subjects to compare the bioavailability and brain distribution of AL001 versus a marketed lithium carbonate product. The trial, which will also be led by Dr. Ovidiu Andronesi of Harvard University, aim to establish AL001's safe, effective, and tolerable dosing requirements. The potential to avoid the need for therapeutic drug monitoring (TDM) is also significant, as it could simplify treatment regimens and improve patient compliance. By potentially offering a safer and more effective alternative to traditional lithium treatments, AL001 could revolutionize how Alzheimer's disease is managed. The ability to measure lithium levels directly in the brain and brain structures using advanced imaging techniques will provide invaluable insights into the drug’s efficacy and safety. This approach not only enhances our understanding of how AL001 works but also supports its potential approval through a Section 505(b)(2) pathway with the FDA. If successful, the trial could pave the way for a new era in Alzheimer's treatment, providing hope for millions of patients and their families. Financial Support for Clinical Trial In addition to this groundbreaking partnership, Alzamend Neuro, Inc. (NASDAQ:ALZN) recently secured the first two tranches of a $25 million Series A purchasing agreement. This investment supports the advancement of Alzamend 's clinical trial and the development of next-generation treatments for Alzheimer’s, bipolar disorder, MDD, and PTSD. CEO Stephan Jackman emphasized the company's dedication to advancing clinical milestones and revolutionizing lithium-based therapies for millions affected by these conditions. Click here for more information about Alzamend Neuro, Inc. (NASDAQ:ALZN). [1] https://www.who.int/health-topics/mental-health#tab=tab_2 Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Alzamend Neuro, Inc. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-alzn. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Alzamend Neuro, Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Alzamend Neuro, Inc.’s industry; (b) market opportunity; (c) Alzamend Neuro, Inc.’s business plans and strategies; (d) services that Alzamend Neuro, Inc. intends to offer; (e) Alzamend Neuro, Inc.’s milestone projections and targets; (f) Alzamend Neuro, Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Alzamend Neuro, Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Alzamend Neuro, Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Alzamend Neuro, Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Alzamend Neuro, Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Alzamend Neuro, Inc.’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Alzamend Neuro, Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Alzamend Neuro, Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Alzamend Neuro, Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Alzamend Neuro, Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Alzamend Neuro, Inc.’s business operations (e) Alzamend Neuro, Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Alzamend Neuro, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Alzamend Neuro, Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Alzamend Neuro, Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Alzamend Neuro, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Alzamend Neuro, Inc. or such entities and are not necessarily indicative of future performance of Alzamend Neuro, Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on pressreach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com
August 06, 2024 09:00 AM Eastern Daylight Time
Image
Digital Asset DirectWhat’s Cool for School 2024
News Media Group, Inc.
Contact Details Karl Wayne +1 334-440-6397 karl@newsmg.com Company Website https://newsmg.com/
August 01, 2024 01:10 PM Eastern Daylight Time
Video
News ReleaseWire Media Group Expands U.S. Reach to 50M+ in 2024
WagerWire
Wire Industries, Inc., a technology and media company that owns and operates sports betting marketplace WagerWire, fantasy sports marketplace FantasyWire, and media division Wire Media Group (WMG), announced today it has hit a significant milestone in the growth of Wire Media Group. WMG content has been viewed over 250M times in the last year and has been featured in the New York Post, USA Today, Bleacher Report, ESPN, Bloomberg and CNBC, among others, collectively reaching 50M+ sports fans with its own content in the first half of 2024. The Wire Media Group has rapidly risen in popularity, fueled by a community of sports fans and bettors enjoying viral stories of life-changing bets trading on the WagerWire marketplace, daily sports and betting news and analysis, and pop culture. “The Wire” is a content collective of top-tier creators and networks as well as original in-house content, with partners including Betr Media, Pro League Network (PLN), The Hammer Betting Network, East Coast Sports Investors, WalterPicks, and Brad Evan’s The Gaming Juice. The WMG content technology team, led by Allan Valle, has built and trained an A.I. content aggregation and amplification system to rapidly clip and syndicate partner content across mediums and channels. The cutting-edge system analyzes trends and cross-targets audiences, breaking partner networks and creators out of their algorithmic silos, resulting in increased discoverability. In addition to engaging content, WagerWire’s popular betting free tools including their Bet Value Calculator and Bet Graphs amass thousands of hits a day. “We create content by fans, for fans and The Wire Media Group was engineered to have something to offer to everyone,” said Travis Geiger, Co-founder and Chief Experience Officer of Wire Industries, Inc. “It’s weird to us that companies who literally profit off their player’s losses are out there giving picks and advice – and worst of all, paying lip service to the idea of responsibility while laughing out loud about degeneracy. People are smart enough to see through the shill. The Wire doesn’t have a hidden agenda. We answer to our community and no one else and we have the freedom to be creative and honest in all we do. What we offer is different, and we’re pleased at the positive response we’ve received to date.” The Wire Media Group also operates the company's affiliate marketing division, The Sports Influencers, which has seen tremendous growth in the first half of 2024. The program has seen 378% growth since the start of the year, growing 40% month-over-month, and has affiliate deals with FanDuel, Caesars, BetMGM, and Betr, to name a few. The Sports Influencers are operating in 23 states, Washington DC, Ontario and Puerto Rico. WagerWire recently won the EGR Rising Star of the Year award and was shortlisted for Rising Star of the Year and Affiliate of the Year at SBC North America, as well as Best X Presence at the Hashtag Sports Awards. WagerWire was also named to Business Insider’s list of 25 promising sports startups to watch, according to VC’s and other top investors. FantasyWire was shortlisted as Innovation of the Year by the Fantasy Sports and Gaming Association (FSGA). WagerWire burst onto the scene in 2022 with the announcement of a high-profile seed round led by Miami Marlins co-owner Roger Ehrenberg and including Betr/Simplebet Founder Joey Levy’s 305 Ventures, NBA All-Star Richard Jefferson, famed ‘Big Short’ investor Danny Moses, sports executive David Meltzer, and more. About Wire Industries Wire Industries Inc. was established in 2021 and owns and operates Wire Technologies and Wire Media Group. Wire Technologies is the company’s marketplace division including WagerWire, FantasyWire, PonyWire and ContestWire, while Wire Media Group operates their media network and affiliate marketing division. The business was founded with the mission to bring a more efficient, open, and entertaining market to real money gaming of all types, unlocking value for the entire ecosystem. You can download their flagship product WagerWire in the Apple App Store and Google Play, and find them @WagerWire on Twitter/X, TikTok and LinkedIn, or @WagerWireLive on Instagram. Wire Industries is dedicated to providing a responsible gaming environment. If you think you or someone you know may have a gambling problem, resources are available. Call 1-800-GAMBLER or reach out to their Chief Responsibly Officer Carolina Young directly at live@wagerwire.com. Contact Details Bailey Irelan birelan@hotpaperlantern.com Company Website https://www.wagerwire.com/
August 01, 2024 10:40 AM Eastern Daylight Time
News ReleaseLizzie Lu Luxury Treats Launches on Amazon, Celebrating August as National Black Business Month
Rev Up Marketers
Lizzie Lu Luxury Treats, a premium confectionery brand known for its unique candy barks, announces its official launch on Amazon.com. This expansion allows candy enthusiasts nationwide to access a variety of flavors, including S’mores, Banana Pudding, Dreamscape, Gorilla Bark, Mint Chocolate Chip, Strawberry Lemonade, Sunburst Lemon, Sweet and Salty Almond, and The Grynch, each retailing for $9.99. Lizzie Lu Luxury Treats uses the finest cocoa beans and premium ingredients, ensuring a high-quality product with every bite. The brand’s handcrafted delights reflect a commitment to excellence and flavor. Founder T’Juanna Winters expressed her excitement about the new venture: “The launch on Amazon enables Lizzie Lu Luxury Treats to reach a broader audience, sharing our handcrafted candy barks with candy enthusiasts everywhere. Each flavor is carefully crafted with precision and passion.” August is recognized as National Black Business Month, making this launch particularly significant as Lizzie Lu Luxury Treats celebrates its contribution to the black business community. The brand highlights the entrepreneurial spirit and dedication of black-owned businesses, offering a unique confectionery experience. For more information, visit Lizzie Lu Luxury Treats at https://lizzieluluxury-treats.com or find their products on Amazon. About Lizzie Lu Luxury Treats Lizzie Lu Luxury Treats is a gourmet confectionery brand specializing in handcrafted candy barks made from premium ingredients. Founded by T’Juanna Winters, Lizzie Lu Luxury Treats aims to bring joy and sweetness to every occasion with its unique and delectable flavors. The brand is committed to quality, creativity, and celebrating the rich heritage of black entrepreneurship. Contact Details Lizzie Lu Luxury Treats Danika Berry danika@lizzieluluxury-treats.com Company Website https://lizzieluluxury-treats.com
August 01, 2024 10:15 AM Eastern Daylight Time
Image
News ReleaseChelsea Piers Fitness Unveils a Luxurious 60,000-Square-Foot Club in Flatiron
Chelsea Piers Fitness
Chelsea Piers Fitness today announced the opening of its Flatiron club at 308 Park Ave S in One Madison Avenue, marking a significant milestone in the brand’s expansion of its legacy throughout the New York City Metro area. With a focus on supporting the city’s evolution as a leader in sports, fitness, entertainment, and hospitality - Chelsea Piers continues to break down barriers and shape the future of fitness with an inclusive approach that embraces the local community with unique amenities and experiences. Located in the iconic One Madison Avenue building developed by SL Green, Chelsea Piers Fitness Flatiron spans over 60,000 square feet across four floors. This elite facility sets the standard for modern premium fitness, providing cutting-edge amenities such as a contrast therapy suite, meticulously crafted locker rooms that include relaxing steam and sauna experiences, and distinctive studio spaces with salt walls and infrared technology. A strong emphasis on community wellness can be seen throughout the facility as well, with the layout built to cultivate in-person social engagement. From a floor dedicated to co-working and social experiences to Roman bath inspired recovery spaces - Chelsea Piers Fitness is revolutionizing the fitness industry by reimagining the concept of a gym, transforming it into a true community with spaces designed for gathering. "Our expansion into the Flatiron community represents a milestone for Chelsea Piers Fitness, pairing our unmatched fitness experience with one of Manhattan’s most active neighborhoods," said David Tewksbury, CEO and Co-Founder of Chelsea Piers Fitness. "We designed our Flatiron club to be a destination where the community can come together to prioritize health and wellness. With extensive amenities and a strong focus on community and wellbeing, this new location embodies our dedication to making a positive impact on New Yorkers’ lives." To design a space that honors the brand’s deep roots in New York City and the essence of its new locale Chelsea Piers Fitness joined forces with Dan Fink Studio, a distinguished interior design and architecture firm. The club embodies a blend of modernity and heritage, combining cutting-edge wellness technology with timeless architectural motifs reminiscent of New York's iconic public buildings. Paying homage to Chelsea Piers Fitness' legacy, the design artfully integrates elements from its original location — including industrial red trusses and a grand staircase constructed with materials inspired by the flagship Pier 60, and custom leaded stained glass windows to represent the hues of the Hudson River. Furthermore, the club features a curated collection of commissioned artwork from local New York artists that celebrates the Flatiron neighborhood's spirit, adding a distinctive cultural layer to the member experience. “Designing this club was an unbelievable journey, weaving the rich history of both Chelsea Piers Fitness and New York City into an architectural narrative,” said Ariel Calderón, Vice President Architecture and Design at Chelsea Piers Fitness. “Our goal was to create a welcoming and inclusive space that embodies community and New York City’s dynamic spirit – a place where people can gather, exercise, work, and connect, capturing the essence of Chelsea Piers." Chelsea Piers Fitness’ Flatiron facility boasts top-of-the-line amenities and offerings, including: Himalayan Salt-Covered Wall + Infrared Yoga Studios – unique studio spaces that offer a myriad of health & wellness benefits Co-Ed Contrast Therapy Suite – communal wellness space offering opportunities for contrast therapy with a 10-person infrared sauna Boutique Classes – 120+ weekly classes run by top-tier group fitness instructors + personal trainers Fully-Stacked Strength + Cardio Floors – a strength floor offering a 4,000-square-foot multi-functional turf, boxing bags, TRX, olympic platforms, complimentary fitness assessments and more, plus a dedicated cardio floor stacked with a second functional turf, Peloton bikes, a fleet of Woodway equipment, and the only gym in NYC with the new Symbio treadmills from Life Fitness equipment. Massive Members Lounge + Co-Working Space – a 6,000 square foot lounge with numerous library-style tables and privacy booths, and a dedicated quiet-area Luxury Locker Rooms – immaculate steam & sauna experiences crafted with recovery and relaxation in mind, stocked with Malin + Goetz personal care products For more information about Chelsea Piers Fitness Flatiron and membership opportunities, visit fitness.chelseapiers.com/locations/flatiron. About Chelsea Piers Fitness The Chelsea Piers brand represents the New York Metro area’s most dynamic sports and fitness center with its original 28-acre waterfront sports village complex located between 17th and 23rd Streets along Manhattan’s Hudson River. Chelsea Piers opened in 1995, transforming four historic, but long-neglected, piers into a major center for public recreation and waterfront access. Situated on Piers 59, 60, and 61 in the head house that connects them, Chelsea Piers features the Golf Club, Field House, Sky Rink, Chelsea Piers Fitness, and Bowlero at Chelsea Piers; the Pier Sixty, Lighthouse, and Current event centers; along with movie and television studios and The Marina at Chelsea Piers. In June 2018, Chelsea Piers opened its first stand-alone fitness club, Chelsea Piers Fitness in Downtown Brooklyn. The Chelsea Piers Fitness brand redefines the traditional gym experience, incorporating state-of-the-art training options, studio-quality class experiences, open creative spaces, unique design, and first-rate customer service. The clubs offer a wide array of traditional fitness options such as hot yoga, Pilates, cycle, strength, and cardio as well as sports specific fitness options like swimming, boxing, rock climbing, basketball, and sand volleyball. Chelsea Piers Fitness club locations include Chelsea, Downtown Brooklyn, Flatiron, Prospect Heights Brooklyn, and Stamford CT. About SL Green Realty Corp. SL Green Realty Corp., Manhattan's largest office landlord, is a fully integrated real estate investment trust, or REIT, that is focused primarily on acquiring, managing and maximizing the value of Manhattan commercial properties. As of June 30, 2024, SL Green held interests in 55 buildings totaling 31.8 million square feet. This included ownership interests in 28.1 million square feet of Manhattan buildings and 2.8 million square feet securing debt and preferred equity investments. About One Madison Avenue Developed by SL Green Realty Corp., One Madison Avenue is a 27-story newly developed office tower located in Midtown South, adjacent to Madison Square Park. The 1.4 million-square-foot office tower provides the highest standard for today’s workplace with forward-thinking amenities and a cutting-edge healthy work environment, in addition to an amenity-rich and curated retail collection at the base of the building. It features oversized roof terraces, “The Commons”, a 7,000-square-foot tenant-only amenity space and Le Jardin sur Madison, a one-of-a-kind 6,200-square-foot rooftop event space designed by renowned architect David Rockwell with a lushly landscaped 5,000-square-foot rooftop garden by SMI Landscape Architecture. The newly transformed office tower will also feature La Tête d’Or, a refined steakhouse by Michelin-starred Chef Daniel Boulud. Notable tenants include Chelsea Piers Fitness, International Business Machines Corporation (“IBM”), Franklin Templeton, Coinbase, Palo Alto and FanDuel. Contact Details Powers PR Alex Turk alext@powers-pr.com Company Website https://fitness.chelseapiers.com
August 01, 2024 09:12 AM Eastern Daylight Time
Image
News ReleaseRenowned Family-Run Hospitality Group Takes Over Three Iconic Virginia Dining Destinations
Pack Brothers Hospitality
Pack Brothers Hospitality is thrilled to announce the expansion of its esteemed portfolio with the addition of three iconic dining establishments, bringing a new level of excellence and personal touch to Virginia’s vibrant culinary scene. The new additions—Decoys Seafood and Bennetts Creek Marina, Vintage Tavern, and River Stone Chophouse—promise to deliver memorable dining experiences, each with its own distinct flavor and atmosphere. A Legacy of Excellence in Hospitality As a family-run duo, Pack Brothers Hospitality has a proven track record of quality, attention to detail, hospitality, and being community-minded. Known for their exceptional restaurants and hotels across Virginia, the Pack Brothers have cultivated a reputation for delivering unforgettable experiences through meticulous attention to detail and a genuine passion for hospitality at properties like Smithfield Station in Smithfield, Virginia, and The Surry Seafood Company in Surry, Virginia. “We are excited to welcome Decoys Seafood, Vintage Tavern, and River Stone Chophouse into the Pack Brothers family,” said Randy Pack, Co-Founder of Pack Brothers Hospitality. “Each of these restaurants has a storied history and a loyal following, and we are honored to build on their success. Our mission is to preserve the unique character of these establishments while infusing them with our commitment to excellence and personal service.” Introducing The Newest Additions in Suffolk, Virginia DECOYS Seafood Restaurant and Bennetts Creek Marina Waterfront Restaurant, Blind Duck Tiki Bar, Bennetts Creek Marina, and Cottages on the Point Escape the hustle and head to Decoys, with its stunning views of Bennetts Creek. This restaurant specializes in an innovative menu that features a range of gourmet comfort foods, from artisanal burgers and hand-cut fries to creative seafood dishes and farm-fresh salads. With its on-site seafood restaurant, 60-slip marina, The Blind Duck Tiki Bar featuring live entertainment on the weekends on its deck, and four luxurious cottages for your overnight stay, Decoys has a warm, inviting ambiance and is set to become the go-to spot for both casual dining and special occasions. VINTAGE TAVERN Step into a restaurant with genuine character where great food is served without pretension. A place that welcomes guests with a relaxed atmosphere and surrounds them with rustic arts and crafts architecture such as exposed beams, Rumsford fireplaces in each dining room, and game trophies in the lounge. From the exhibition kitchen come signature dishes prepared by the culinary team, among them an appetizing Taste of Southern Goodness sampler of homemade biscuits, house-made sausages, shaved Virginia ham, deviled eggs, house-made spreads such as strawberry jam, and seasonal entrees like oven-baked flounder with herb-onion spoon bread and lemon brown butter sauce. Vintage Tavern just received its two-stem award from Wine Spectator, showcasing its deep commitment to wine. The menu is truly Seasonally Southern. RIVER STONE CHOPHOUSE The River Stone Chophouse is Coastal Virginia’s premier Chophouse featuring Steaks, Seafood, and Raw Bar. The only restaurant locally aging Hereford Beef and custom cutting our own steaks to delight every carnivore. Signature dishes include a 22 oz. Dry Aged Ribeye, aged in-house for 28 days, Deviled Crab Dip, and Live Maine Lobsters. A rotating selection of oysters, plus seasonal salads and sides, complete the dining experience. Exceptional service combined with a carefully selected Two Stem award-winning wine list makes dining at River Stone an unforgettable experience. The Arts and Crafts inspired space includes a stone fireplace, romantic booths, dramatic lighting, an oyster and raw bar, and a vibrant bar scene featuring Happy Hour every weekday. A separate bar menu offers more casual selections including a ½ lb burger, House Cut Fries, and a Philly Steak Spring Roll. Outside the bar, the stone patio with a fire pit offers a relaxing atmosphere for an after-dinner cocktail or to enjoy a fine cigar. The second floor offers four private rooms with exceptional audio-visual to accommodate all your meeting needs. A New Chapter for Virginia’s Culinary Scene The acquisition of these celebrated restaurants marks an exciting new chapter for Pack Brothers Hospitality. The Pack brothers' passion for creating outstanding dining experiences and their commitment to maintaining high standards of quality and service will ensure that Decoys Seafood and Bennetts Creek Marina, Vintage Tavern, and River Stone Chophouse continue to be beloved destinations for locals and visitors alike. “We look forward to the dedicated teams at each restaurant and working together to uphold the high standards that these establishments are known for,” said Randy Pack, Co-Founder of Pack Brothers Hospitality. “Our goal is to honor the legacy of these iconic restaurants while introducing new elements that will delight our guests and keep these venues at the forefront of Virginia’s dining scene.” Company Links: Website: Pack Brothers Hospitality Decoys | Instagram Bennetts Creek Marina Vintage Tavern | Instagram River Stone Chophouse | Instagram #PackBrothersHospitality #VirginiaDining #DecoysSeafood #BennettsCreekMarina #VintageTavern #RiverStoneChophouse #SuffolkVirginiaRestaurants #FamilyRunHospitality #CoastalVirginiaCuisine #GourmetComfortFoods #SeasonallySouthern #WineSpectatorAward #HerefordBeef #Chophouse #RawBar #FineDiningVirginia About Pack Brothers Hospitality Experience Exceptional Hospitality: Discover a realm where luxury intertwines with approachability and warmth, where every detail is meticulously crafted to exceed your expectations. Pack Brothers collection of properties offers a sanctuary for those seeking refinement and rejuvenation along the Virginia coastlines. At Pack Brothers Hospitality, hospitality is not just a service—it’s a passion. Our dedicated team is committed to anticipating your every need and ensuring that your experience with us is nothing short of exceptional. Pack Brothers Hospitality is a family-owned and operated company known for its exceptional restaurants and hotels across Coastal Virginia. With a focus on quality, innovation, and personalized service, Pack Brothers Hospitality has established a reputation for creating memorable experiences that reflect a deep passion for hospitality and community. Contact Details Pack Brothers Hospitaltiy Randy Pack +1 757-357-7700 randy.pack@packbrothershospitality.com Company Website https://www.packbrothershospitality.com/
August 01, 2024 09:00 AM Eastern Daylight Time
Image